Thomas Mulier is an editor and journalist who has written for various publications including BNN Bloomberg, Bloomberg News, and Yahoo Finance. His articles cover a range of topics including business, finance, and the pharmaceutical industry. Thomas has a keen interest in reporting on company news, market trends, and the impact of technology on various industries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Not enough data
Thomas Mulier's coverage predominantly focuses on the healthcare and pharmaceutical industries, with attention to business developments in these sectors. He often cites data, reports private sector announcements, and provides investment analysis.
Given his focus on healthcare and pharmaceuticals, Thomas would likely be interested in pitches that offer insights into industry trends, new product releases or advancements in medical technology. Experts who can provide data-driven analysis of market trends or discuss innovations within the pharmaceutical space may particularly resonate with him.
Additionally, as he often covers private sector announcements and investment analyses related to health-related businesses, sources providing insider perspectives on mergers & acquisitions or financial performances within this industry could capture his interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
(Bloomberg) -- Burberry Group Plc lowered its profit forecast after sales in the key month of December fell.
Burberry Plunges as UK Trenchcoat Maker Slashes Profit Forecast
(Bloomberg) -- Lonza Group AG shares rose the most ever after the Swiss maker of drug ingredients reported better-than-expected earnings and named Jean-Marc Huet as its new chairman.
Der Schweizer Pharmahersteller Lonza war am Freitag an der Zürcher Börse gesucht, nachdem er mit seinen Zahlen für das vergangene Jahr die Erwartungen übertraf und einen neuen Verwaltungsratspräsidenten bekanntgab.
Motor Fuel Group agreed to buy 337 gas stations and more than 400 electric-vehicle charging sites from Morrisons in a deal worth £2.5 billion ($3.2 billion).
MorphoSys AG shares surged after a report that Novartis AG is in advanced talks to buy the German maker of cancer treatments.
By: John Lauerman, Thomas Mulier
Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion), adding the German drugmaker's cancer treatments to its pipeline.
By: Thomas Mulier, John Lauerman
Novartis will MorphoSys für einen Eigenkapitalwert von 2,7 Milliarden Euro übernehmen und damit die Krebstherapie-Pipeline des Biotech-Unternehmens aus Planegg bei München.
By: Thomas Mulier, John Lauerman
(Bloomberg) -- Novartis AG agreed to buy MorphoSys AG for €2.7 billion ($2.9 billion), adding the German drugmaker's cancer treatments to its pipeline, which the Swiss pharma company has been trying to beef up.
By: Dasha Afanasieva, Thomas Mulier
Nestle SA Chief Executive Officer Mark Schneider said GLP-1 obesity drugs like Wegovy will probably increase demand for a range of food products that can help avoid nutrient deficiencies.
(833) 317-6278 
